30.05.2018
PET-CT examinations will be conducted in the new nuclear medicine department at the Hôpital de La Tour located in building B2 (lower level) as of Tuesday 19 June 2018.

The following examinations covered by the compulsory health insurance scheme* are provided:

  •  Oncology: 18F-FDG PET-CT imaging (all cancer types except 1), 18F-choline PET-CT imaging (for biochemical recurrence of prostate cancer1)

o   Indications: staging, assessment of therapeutic response, radiation planning, recurrence definition, follow-up, etc…

o   In the light of current developments, the exploration of neural endocrine tumours should first be discussed between the consulting doctor and the nuclear medicine specialist.

  • Neurology (neurodegenerative diseases, dementias, epilepsy): 18F-FDG cerebral PET-CT imaging
  • Cardiology: heart disease analysis, search for endocarditis/cardiac sarcoidosis.
  • Internal medicine: search for deep-seated infectious diseases (sepsis of unknown origin, vascular prosthesis infection, endocarditis, etc.), systemic inflammatory pathologies (vasculitis, sarcoidosis, etc.), mass effect examination.

After 1st June 2018, applications for examinations may be submitted to the secretary of the nuclear medicine department using the appropriate forms. It is mandatory to state the patient's weight in the application, since the amount of product to be injected and thus ordered is to be calculated from this value.

The examinations will initially be conducted primarily on Tuesdays, Thursdays and Fridays.

For any medical questions, please contact Dr. med. Renaud Guignard on 022 719 75 14 or by e-mail at renaud.guignard@latour.ch.

With regard to questions concerning the examination procedure, the SMN team remains entirely at your disposal and that of your own teams.

Useful information may be obtained at https://www.la-tour.ch/fr/docteurs-et-specialites/specialites-medicales/medecine-nucleaire/

We would furthermore inform you that all other conventional nuclear medicine procedures (SPECT-CT, bone scans) will also resume on Tuesday 19 June 2018 on the afore-mentioned new premises.

*in compliance with the SSMN clinical directives of 28.04.2011

 

Dr. med. Renaud Guignard, head physician, specialist in nuclear medicine, member of FMH

Ms. Dominique Guiguet, director of nuclear medicine, radiation safety officer